Identifying illness parameters in fatiguing syndrome using classical projection methods

University of Alberta, Institute for Biomolecular Design, Edmonton, Alberta, T6G 2H7, Canada.
Pharmacogenomics (Impact Factor: 3.43). 05/2006; 7(3):407-19. DOI: 10.2217/14622416.7.3.407
Source: PubMed

ABSTRACT To examine the potential of multivariate projection methods in identifying common patterns of change in clinical and gene expression data that capture the illness state of subjects with unexplained fatigue and nonfatigued control participants.
Data for 111 female subjects was examined. A total of 59 indicators, including multidimensional fatigue inventory (MFI), medical outcome Short Form 36 (SF-36), Centers for Disease Control and Prevention (CDC) symptom inventory and cognitive response described illness. Partial least squares (PLS) was used to construct two feature spaces: one describing the symptom space from gene expression in peripheral blood mononuclear cells (PBMC) and one based on 117 clinical variables. Multiplicative scatter correction followed by quantile normalization was applied for trend removal and range adjustment of microarray data. Microarray quality was assessed using mean Pearson correlation between samples. Benjamini-Hochberg multiple testing criteria served to identify significantly expressed probes.
A single common trend in 59 symptom constructs isolates of nonfatigued subjects from the overall group. This segregation is supported by two co-regulation patterns representing 10% of the overall microarray variation. Of the 39 principal contributors, the 17 probes annotated related to basic cellular processes involved in cell signaling, ion transport and immune system function. The single most influential gene was sestrin 1 (SESN1), supporting recent evidence of oxidative stress involvement in chronic fatigue syndrome (CFS). Dominant variables in the clinical feature space described heart rate variability (HRV) during sleep. Potassium and free thyroxine (T4) also figure prominently.
Combining multiple symptom, gene or clinical variables into composite features provides better discrimination of the illness state than even the most influential variable used alone. Although the exact mechanism is unclear, results suggest a common link between oxidative stress, immune system dysfunction and potassium imbalance in CFS patients leading to impaired sympatho-vagal balance strongly reflected in abnormal HRV.

Download full-text


Available from: Toni Whistler, Aug 10, 2015
1 Follower
  • Source
    • "Immunological aberrations (inflammation, immune activation, immunosuppression and immune dysfunction); Klimas et al., 1990; Fletcher et al., 2009; Lorusso et al., 2009; Meeus et al., 2009; Brenu et al., 2011; Maes et al., 2012b consistent with processes observed during (latent) infection; Lloyd et al., 1993; Kerr et al., 2008a; Broderick et al., 2010 Intestinal dysbiosis, inflammation and hyperpermeability, Maes et al., 2007a; Sheedy et al., 2009; Lakhan and Kirchgessner, 2010; De Meirleir et al., 2013; Frémont et al., 2013 associated with systemic immune system abnormalities; Maes et al., 2012c; Groeger et al., 2013 (reactivating and/or persistent) infections; Hilgers and Frank, 1996; Chia and Chia, 2003; Nicolson et al., 2003; Chia et al., 2010; Chapenko et al., 2012 Elevated oxidative and nitrosative stress; Zhang et al., 1995; Kennedy et al., 2010; Maes and Twisk, 2010; Tomic et al., 2012 Mitochondrial dysfunction and damage to mitochondria; Behan et al., 1991; Pietrangelo et al., 2009; Booth et al., 2012; Meeus et al., 2013 Hypovolemia, diminished cardiac output and Streeten and Bell, 1998; Hurwitz et al., 2009; Miwa and Fujita, 2009; Hollingsworth et al., 2012 blood and oxygen supply deficits to muscles and brain, McCully and Natelson, 1999; Biswal et al., 2011; Ocon, 2013 especially in an upright position and during exercise; LaManca et al., 1999; Peckerman et al., 2003; Wyller et al., 2007; Patrick Neary et al., 2008 Reduced (maximum) oxygen uptake; Farquhar et al., 2002; Weinstein et al., 2009; Vermeulen et al., 2010; Jones et al., 2012 Neurological abnormalities; Lange et al., 2005; Chen et al., 2008; Puri et al., 2012; Natelson, 2013 Hypocortisolism/blunted hypothalamic-pituitary-adrenal (HPA) axis response; Demitrack et al., 1991; Lorusso et al., 2009; Papadopoulos and Cleare, 2011; Tak et al., 2011 Ion channel dysfunction (channelopathy); Watson et al., 1997; Whistler et al., 2005; Broderick et al., 2006; Cameron et al., 2007 A deviant physiological responses to exertion Thambirajah et al., 2008; Jones et al., 2012; Light et al., 2012; Smylie et al., 2013; Snell et al., 2013 (Kindlon, 2012), e.g., oxygen uptake at the anaerobic threshold and maximum oxygen uptake (VO2max), and biomarkers, e.g., (exercise-induced) cytokine levels. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Myalgic Encephalomyelitis (ME) was identified as a new clinical entity in 1959 and has been acknowledged as a disease of the central nervous system/neurological disease by the World Health Organisation since 1969. Cognitive impairment, (muscle) weakness, circulatory disturbances, marked variability of symptoms, and, above all, post-exertional malaise: a long-lasting increase of symptoms after minor exertion, are distinctive symptoms of ME.Chronic Fatigue Syndrome (CFS) was introduced in 1988 and was redefined into clinically evaluated, unexplained (persistent or relapsing) chronic fatigue, accompanied by at least four out of a list of eight symptoms, e.g. headaches and unrefreshing sleep, in 1994.Although the labels are used interchangeably, ME and CFS define distinct diagnostic entities. Post-exertional malaise and cognitive deficits e.g. are not mandatory for the diagnosis CFS, while obligatory for the diagnosis ME. “Fatigue” is not obligatory for the diagnosis ME.Since fatigue and other symptoms are subjective and ambiguous, research has been hampered. Despite this and other methodological issues, research has observed specific abnormalities in ME/CFS repetitively, e.g. immunological abnormalities, oxidative and nitrosative
    Frontiers in Physiology 03/2014; 5:109. DOI:10.3389/fphys.2014.00109 · 3.50 Impact Factor
  • Source
    • "Twenty-four genes and 11 pathways common between the 2 subsets indicate a difference in eg immune response, apoptotic activity, and ion channel activity. Broderick et al (2006) "
    [Show abstract] [Hide abstract]
    ABSTRACT: Fatigue is a common symptom and includes both physical and mental components. It can be associated with a variety of different syndromes and diseases, but in many cases is not associated with other comorbid conditions. Most humans have experienced acute fatigue in relation to different stressors. Acute fatigue typically decreases as the effect of the triggering factor is reduced and a normal homeostatic balance is restored. Fatigue that persists for 6 months or more is termed chronic fatigue. Chronic fatigue (CF) in combination with a minimum of 4 of 8 symptoms and the absence of diseases that could explain these symptoms, constitute the case definition for chronic fatigue syndrome. In spite of its prevalence, the biology of fatigue is relatively poorly understood and biological markers have not yet been identified. This literature search was performed in PubMed to identify research on the genetics and epigenetics of fatigue. Publications were included if fatigue was a major topic and the topic was combined with genetic and/or epigenetic measurements in adult humans. A total of 40 publications were identified. Although altered functioning in the hypothalamic-pituitary-adrenal axis, the serotonergic system, and associations with infectious agents have been identified, the search for genetic or epigenetic markers of fatigue, either in the context of CF or chronic fatigue syndrome (CFS) has been relatively unproductive or, in the case of epigenetics, nonexistent. Although several studies, both hypothesis-testing and hypothesis-generating, have been performed to search for biomarkers, they have mostly been underpowered, restricted by the heterogeneity of the phenotype, or limited by an unsystematic study design. To be able to confirm the hypothesis that risk for, or levels of, fatigue are influenced by the genetic or epigenetic background of an individual, studies need to be based on larger sample sizes with a more clearly defined phenotype. Studies need to focus not only on the influence of a single aspect such as single nucleotide polymorphisms (SNPs) or differential gene expression on disease risk or state, but also on the systems biology behind the disease in combination with information on environmental influences and validation of findings in functional studies.
    PM&R 05/2010; 2(5):456-65. DOI:10.1016/j.pmrj.2010.04.003 · 1.66 Impact Factor
  • Source
    • "Over time researchers have shown various immune system abnormalities, like decrea sed natural killer cell activity (Saiki et al. 2008; Nijs & de Meirleir, 2005; Klimas et al. 1990), reduced perforin levels in cytotoxic T and NK cells (Maher et al. 2005), defects in T-and NK cell activation (Mihaylova et al. 2007; Maes et al. 2006), a significant decrease in the suppressor inducer subset of CD4+CD45RA+ cells (Klimas et al. 1990), a significant bias towards Th2-and Tc2-type immune responses (Skowera et al. 2004), and dysregula tion of the RNAse L pathway (Suhadolnik et al. 1997; Englebienne & de Meirleir, 2002; Tiev et al. 2003). A central role for immune system abnormalities , inflammation and immune dysfunction, in the pathophysiology of ME/CFS have also been implicated by several gene expression studies (Kaushik et al. 2005; Kerr et al. 2008; Broderick et al. 2006; Aspler et al. 2008, Gow et al. 2009). Inflammation, leading to per ma nently increased oxidative and nitrosative stress, on the one hand, and a chronically de pressed and dysfunctional immune system on the other hand, adequately explain many biological abnormalities found in ME/CFS, resulting into typical ME/CFS complaints. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Benign Myalgic Encephalomyelitis (ME) / Chronic Fatigue Syndrome (CFS) is a debilitating disease which, despite numerous biological abnormalities has remained highly controversial. Notwithstanding the medical pathogenesis of ME/CFS, the (bio)psychosocial model is adopted by many governmental organizations and medical profes-sio-nals to legitimize the combination of Cognitive Behavioral Therapy (CBT) and Graded Exercise Therapy (GET) for ME/CFS. Justified by this model CBT and GET aim at eliminating presumed psychogenic and socially induced maintaining factors and reversing deconditioning, respectively. In this review we invalidate the (bio)psychosocial model for ME/CFS and demonstrate that the success claim for CBT/GET to treat ME/CFS is unjust. CBT/GET is not only hardly more effective than non-interventions or standard medical care, but many patients report that the therapy had affected them adversely, the majority of them even reporting substantial deterioration. Moreover, this review shows that exertion and thus GET most likely have a negative impact on many ME/CFS patients. Exertion induces post-exertional malaise with a decreased physical performan-ce/aerobic capacity, increased muscoskeletal pain, neurocognitive impairment, "fatigue", and weakness, and a long lasting "recovery" time. This can be explained by findings that exertion may amplify pre-existing pa-thophysiological abnormalities underpinning ME/CFS, such as inflammation, immune dysfunction, oxidative and nitrosative stress, channelopathy, defec-tive stress response mechanisms and a hypoactive hypothalamic-pituitary-adrenal axis. We conclude that it is unethical to treat patients with ME/CFS with ineffective, non-evidence-based and potentially harmful "rehabilitation therapies", such as CBT/GET.
    Neuro endocrinology letters 08/2009; 30(3):284-99. · 0.94 Impact Factor
Show more